Angiotensin II Receptor Blockers and Celiac Disease

    Basic Details
    Date Posted
    Monday, January 16, 2012
    Status
    Complete
    Medical Product
    angiotensin II receptor blocker (ARB)
    candesartan
    eprosartan
    irbesartan
    losartan
    olmesartan
    telmisartan
    valsartan
    Health Outcome(s)
    celiac disease
    Description

    Modular program-based one-time assessment of the risk of celiac disease associated with new use of angiotensin II receptor blockers (ARBs). Modular programs are adaptable standardized programs.

    Additional Details
    FDA Center
    CDER
    Study Type
    Modular Program
    Assessment Type
    Exploratory Analyses
    Data Sources
    Mini-Sentinel Distributed Dataset (MSDD)